For additional validation, we tested whether the 54 selected Spectrum/Prestwick drugs as well as all agents in the Sequoia library inhibited a primary MLL-rearranged ALL patient sample to a similar extent as was observed for the ALL cell lines. Here, KMT2A is linked to acute lymphoblastic leukemia.